At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 272 enrolled
Drug / intervention
Donanemab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Donanemab, Placebo, and 1 other intervention for Alzheimer Disease. Completed, enrolled 272 participants across 61 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartDec 2017
Primary CompletionDec 2020
Study CompletionSep 2021
TodayJul 2026
First PostedDec 8, 2017
Enrollment StartDec 18, 2017
Primary CompletionDec 4, 2020
Study CompletionSep 21, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.6 years ago
Interventions
Donanemabdrug
Administered IV
Placebodrug
Administered IV
LY3202626drug
Administered orally